JP2020506695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506695A5 JP2020506695A5 JP2019540667A JP2019540667A JP2020506695A5 JP 2020506695 A5 JP2020506695 A5 JP 2020506695A5 JP 2019540667 A JP2019540667 A JP 2019540667A JP 2019540667 A JP2019540667 A JP 2019540667A JP 2020506695 A5 JP2020506695 A5 JP 2020506695A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vector
- raav
- recombinant
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 4
- 208000005516 glycogen storage disease Ib Diseases 0.000 claims description 4
- 208000011476 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib Diseases 0.000 claims description 3
- 206010018464 Glycogen storage disease type I Diseases 0.000 claims description 3
- 239000013607 AAV vector Substances 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000007345 glycogen storage disease Diseases 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000013647 rAAV8 vector Substances 0.000 claims description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169032A JP2023002715A (ja) | 2017-01-30 | 2022-10-21 | 糖原病を処置するための組換えウイルスベクター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451963P | 2017-01-30 | 2017-01-30 | |
| US62/451,963 | 2017-01-30 | ||
| PCT/US2018/015957 WO2018140946A1 (en) | 2017-01-30 | 2018-01-30 | Recombinant virus vectors for the treatment of glycogen storage disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169032A Division JP2023002715A (ja) | 2017-01-30 | 2022-10-21 | 糖原病を処置するための組換えウイルスベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506695A JP2020506695A (ja) | 2020-03-05 |
| JP2020506695A5 true JP2020506695A5 (enExample) | 2021-02-25 |
Family
ID=61274327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540667A Pending JP2020506695A (ja) | 2017-01-30 | 2018-01-30 | 糖原病を処置するための組換えウイルスベクター |
| JP2022169032A Pending JP2023002715A (ja) | 2017-01-30 | 2022-10-21 | 糖原病を処置するための組換えウイルスベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169032A Pending JP2023002715A (ja) | 2017-01-30 | 2022-10-21 | 糖原病を処置するための組換えウイルスベクター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190367944A1 (enExample) |
| EP (1) | EP3574104A1 (enExample) |
| JP (2) | JP2020506695A (enExample) |
| AU (1) | AU2018212002A1 (enExample) |
| CA (1) | CA3050917A1 (enExample) |
| WO (1) | WO2018140946A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113454226B (zh) * | 2018-12-18 | 2025-10-31 | 阿尔特拉吉尼克斯制药公司 | 用于治疗糖原贮积病的方法和组合物 |
| US20250222134A1 (en) * | 2021-10-19 | 2025-07-10 | University Of Connecticut | Compositions and methods for the treatment of glycogen storage disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| KR100556864B1 (ko) | 1997-05-13 | 2006-03-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 렌티바이러스-기원 유전자 전달 벡터 |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US6759050B1 (en) | 1998-12-03 | 2004-07-06 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| US6218186B1 (en) | 1999-11-12 | 2001-04-17 | Trustees Of The University Of Pennsylvania | HIV-MSCV hybrid viral vector for gene transfer |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| RU2305708C2 (ru) | 2001-10-02 | 2007-09-10 | Энститю Клейтон Де Ля Решерш | Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение |
| EP1581056B1 (en) | 2002-12-13 | 2010-07-21 | Genetix Pharmaceuticals Inc. | Therapeutic retroviral vectors for gene therapy |
| US20050261233A1 (en) * | 2004-04-21 | 2005-11-24 | Sanjay Bhanot | Modulation of glucose-6-phosphatase translocase expression |
| WO2009019612A2 (en) | 2007-08-03 | 2009-02-12 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
| WO2009097129A1 (en) | 2008-01-29 | 2009-08-06 | Applied Genetic Technologies Corporation | Recombinant virus production using mammalian cells in suspension |
| WO2010114948A2 (en) | 2009-04-02 | 2010-10-07 | University Of Florida Research Foundation, Inc. | An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors |
| US20120133514A1 (en) | 2009-06-30 | 2012-05-31 | Asp Technology Aps | Pause adviser system and use thereof |
| PT2529020T (pt) | 2010-01-28 | 2018-07-30 | Childrens Hospital Philadelphia | Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica |
| EP3074510B1 (en) * | 2013-11-26 | 2018-08-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Adeno-associated virus vectors for treatment of glycogen storage disease |
| CA2972038C (en) * | 2014-12-23 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adeno-associated virus vectors encoding modified g6pc and uses thereof |
-
2018
- 2018-01-30 WO PCT/US2018/015957 patent/WO2018140946A1/en not_active Ceased
- 2018-01-30 US US16/481,430 patent/US20190367944A1/en not_active Abandoned
- 2018-01-30 JP JP2019540667A patent/JP2020506695A/ja active Pending
- 2018-01-30 AU AU2018212002A patent/AU2018212002A1/en not_active Abandoned
- 2018-01-30 CA CA3050917A patent/CA3050917A1/en active Pending
- 2018-01-30 EP EP18707167.5A patent/EP3574104A1/en not_active Withdrawn
-
2022
- 2022-10-21 JP JP2022169032A patent/JP2023002715A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538885A5 (enExample) | ||
| JP2024054426A5 (enExample) | ||
| Kaufmann et al. | Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review | |
| JP2014512171A5 (enExample) | ||
| Bobbin et al. | RNA interference approaches for treatment of HIV-1 infection | |
| JP2018501791A5 (enExample) | ||
| JP2010516252A5 (enExample) | ||
| JP2018523668A5 (enExample) | ||
| EP4272728A3 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
| JP2018520997A5 (enExample) | ||
| JP2020514286A5 (enExample) | ||
| WO2019060454A3 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| Zhan et al. | Vectored immunotherapeutics for infectious diseases: Can rAAVs be the game changers for fighting transmissible pathogens? | |
| JP2019521139A5 (enExample) | ||
| CA3011874A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| WO2017197355A3 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| JP2020510447A5 (enExample) | ||
| JP2016537341A5 (enExample) | ||
| JP2019513794A5 (enExample) | ||
| JP2020518276A5 (enExample) | ||
| JP2018532428A5 (enExample) | ||
| CA3014631A1 (en) | Excision of retroviral nucleic acid sequences | |
| JP2019515914A5 (enExample) | ||
| JP2020518268A5 (enExample) | ||
| JP2018515101A5 (enExample) |